A SARS-CoV-2-Human Protein-Protein Interaction Map Reveals Drug Targets and Potential Drug-Repurposing.

Autor:	Gordon DE; QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA.; University of California San Francisco, Quantitative Biosciences Institute (QBI), San Francisco, CA, 94158, USA.; J. David Gladstone Institutes, San Francisco, CA 94158, USA.; University of California San Francisco, Department of Cellular and Molecular Pharmacology, San Francisco, CA, 94158, USA., Jang GM; QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA.; University of California San Francisco, Quantitative Biosciences Institute (QBI), San Francisco, CA, 94158, USA.; J. David Gladstone Institutes, San Francisco, CA 94158, USA.; University of California San Francisco, Department of Cellular and Molecular Pharmacology, San Francisco, CA, 94158, USA., Bouhaddou M; QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA.; University of California San Francisco, Quantitative Biosciences Institute (QBI), San Francisco, CA, 94158, USA.; J. David Gladstone Institutes, San Francisco, CA 94158, USA.; University of California San Francisco, Department of Cellular and Molecular Pharmacology, San Francisco, CA, 94158, USA., Xu J; QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA.; University of California San Francisco, Quantitative Biosciences Institute (QBI), San Francisco, CA, 94158, USA.; J. David Gladstone Institutes, San Francisco, CA 94158, USA.; University of California San Francisco, Department of Cellular and Molecular Pharmacology, San Francisco, CA, 94158, USA., Obernier K; QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA.; University of California San Francisco, Quantitative Biosciences Institute (QBI), San Francisco, CA, 94158, USA.; J. David Gladstone Institutes, San Francisco, CA 94158, USA.; University of California San Francisco, Department of Cellular and Molecular Pharmacology, San Francisco, CA, 94158, USA., O'Meara MJ; Department of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, MI, 48109, USA., Guo JZ; QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA.; University of California San Francisco, Quantitative Biosciences Institute (QBI), San Francisco, CA, 94158, USA.; J. David Gladstone Institutes, San Francisco, CA 94158, USA.; University of California San Francisco, Department of Cellular and Molecular Pharmacology, San Francisco, CA, 94158, USA., Swaney DL; QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA.; University of California San Francisco, Quantitative Biosciences Institute (QBI), San Francisco, CA, 94158, USA.; J. David Gladstone Institutes, San Francisco, CA 94158, USA.; University of California San Francisco, Department of Cellular and Molecular Pharmacology, San Francisco, CA, 94158, USA., Tummino TA; QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA.; University of California San Francisco, Quantitative Biosciences Institute (QBI), San Francisco, CA, 94158, USA.; Department of Pharmaceutical Chemistry, University of California, San Francisco., Huettenhain R; QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA.; University of California San Francisco, Quantitative Biosciences Institute (QBI), San Francisco, CA, 94158, USA.; J. David Gladstone Institutes, San Francisco, CA 94158, USA.; University of California San Francisco, Department of Cellular and Molecular Pharmacology, San Francisco, CA, 94158, USA., Kaake RM; QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA.; University of California San Francisco, Quantitative Biosciences Institute (QBI), San Francisco, CA, 94158, USA.; J. David Gladstone Institutes, San Francisco, CA 94158, USA.; University of California San Francisco, Department of Cellular and Molecular Pharmacology, San Francisco, CA, 94158, USA., Richards AL; QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA.; University of California San Francisco, Quantitative Biosciences Institute (QBI), San Francisco, CA, 94158, USA.; J. David Gladstone Institutes, San Francisco, CA 94158, USA.; University of California San Francisco, Department of Cellular and Molecular Pharmacology, San Francisco, CA, 94158, USA., Tutuncuoglu B; QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA.; University of California San Francisco, Quantitative Biosciences Institute (QBI), San Francisco, CA, 94158, USA.; J. David Gladstone Institutes, San Francisco, CA 94158, USA.; University of California San Francisco, Department of Cellular and Molecular Pharmacology, San Francisco, CA, 94158, USA., Foussard H; QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA.; University of California San Francisco, Quantitative Biosciences Institute (QBI), San Francisco, CA, 94158, USA.; J. David Gladstone Institutes, San Francisco, CA 94158, USA.; University of California San Francisco, Department of Cellular and Molecular Pharmacology, San Francisco, CA, 94158, USA., Batra J; QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA.; University of California San Francisco, Quantitative Biosciences Institute (QBI), San Francisco, CA, 94158, USA.; J. David Gladstone Institutes, San Francisco, CA 94158, USA.; University of California San Francisco, Department of Cellular and Molecular Pharmacology, San Francisco, CA, 94158, USA., Haas K; QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA.; University of California San Francisco, Quantitative Biosciences Institute (QBI), San Francisco, CA, 94158, USA.; J. David Gladstone Institutes, San Francisco, CA 94158, USA.; University of California San Francisco, Department of Cellular and Molecular Pharmacology, San Francisco, CA, 94158, USA., Modak M; QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA.; University of California San Francisco, Quantitative Biosciences Institute (QBI), San Francisco, CA, 94158, USA.; J. David Gladstone Institutes, San Francisco, CA 94158, USA.; University of California San Francisco, Department of Cellular and Molecular Pharmacology, San Francisco, CA, 94158, USA., Kim M; QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA.; University of California San Francisco, Quantitative Biosciences Institute (QBI), San Francisco, CA, 94158, USA.; J. David Gladstone Institutes, San Francisco, CA 94158, USA.; University of California San Francisco, Department of Cellular and Molecular Pharmacology, San Francisco, CA, 94158, USA., Haas P; QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA.; University of California San Francisco, Quantitative Biosciences Institute (QBI), San Francisco, CA, 94158, USA.; J. David Gladstone Institutes, San Francisco, CA 94158, USA.; University of California San Francisco, Department of Cellular and Molecular Pharmacology, San Francisco, CA, 94158, USA., Polacco BJ; QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA.; University of California San Francisco, Quantitative Biosciences Institute (QBI), San Francisco, CA, 94158, USA.; J. David Gladstone Institutes, San Francisco, CA 94158, USA.; University of California San Francisco, Department of Cellular and Molecular Pharmacology, San Francisco, CA, 94158, USA., Braberg H; QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA.; University of California San Francisco, Quantitative Biosciences Institute (QBI), San Francisco, CA, 94158, USA.; J. David Gladstone Institutes, San Francisco, CA 94158, USA.; University of California San Francisco, Department of Cellular and Molecular Pharmacology, San Francisco, CA, 94158, USA., Fabius JM; QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA.; University of California San Francisco, Quantitative Biosciences Institute (QBI), San Francisco, CA, 94158, USA.; J. David Gladstone Institutes, San Francisco, CA 94158, USA.; University of California San Francisco, Department of Cellular and Molecular Pharmacology, San Francisco, CA, 94158, USA., Eckhardt M; QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA.; University of California San Francisco, Quantitative Biosciences Institute (QBI), San Francisco, CA, 94158, USA.; J. David Gladstone Institutes, San Francisco, CA 94158, USA.; University of California San Francisco, Department of Cellular and Molecular Pharmacology, San Francisco, CA, 94158, USA., Soucheray M; QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA.; University of California San Francisco, Quantitative Biosciences Institute (QBI), San Francisco, CA, 94158, USA.; J. David Gladstone Institutes, San Francisco, CA 94158, USA.; University of California San Francisco, Department of Cellular and Molecular Pharmacology, San Francisco, CA, 94158, USA., Bennett MJ; QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA.; University of California San Francisco, Quantitative Biosciences Institute (QBI), San Francisco, CA, 94158, USA.; J. David Gladstone Institutes, San Francisco, CA 94158, USA.; University of California San Francisco, Department of Cellular and Molecular Pharmacology, San Francisco, CA, 94158, USA., Cakir M; QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA.; University of California San Francisco, Quantitative Biosciences Institute (QBI), San Francisco, CA, 94158, USA.; J. David Gladstone Institutes, San Francisco, CA 94158, USA.; University of California San Francisco, Department of Cellular and Molecular Pharmacology, San Francisco, CA, 94158, USA., McGregor MJ; QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA.; University of California San Francisco, Quantitative Biosciences Institute (QBI), San Francisco, CA, 94158, USA.; J. David Gladstone Institutes, San Francisco, CA 94158, USA.; University of California San Francisco, Department of Cellular and Molecular Pharmacology, San Francisco, CA, 94158, USA., Li Q; QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA.; University of California San Francisco, Quantitative Biosciences Institute (QBI), San Francisco, CA, 94158, USA.; J. David Gladstone Institutes, San Francisco, CA 94158, USA.; University of California San Francisco, Department of Cellular and Molecular Pharmacology, San Francisco, CA, 94158, USA., Naing ZZC; QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA.; University of California San Francisco, Quantitative Biosciences Institute (QBI), San Francisco, CA, 94158, USA.; J. David Gladstone Institutes, San Francisco, CA 94158, USA.; University of California San Francisco, Department of Cellular and Molecular Pharmacology, San Francisco, CA, 94158, USA., Zhou Y; QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA.; University of California San Francisco, Quantitative Biosciences Institute (QBI), San Francisco, CA, 94158, USA.; J. David Gladstone Institutes, San Francisco, CA 94158, USA.; University of California San Francisco, Department of Cellular and Molecular Pharmacology, San Francisco, CA, 94158, USA., Peng S; QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA.; University of California San Francisco, Quantitative Biosciences Institute (QBI), San Francisco, CA, 94158, USA.; Department of Pharmaceutical Chemistry, University of California, San Francisco., Kirby IT; QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA.; University of California San Francisco, Department of Cellular and Molecular Pharmacology, San Francisco, CA, 94158, USA.; Howard Hughes Medical Institute., Melnyk JE; QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA.; University of California San Francisco, Department of Cellular and Molecular Pharmacology, San Francisco, CA, 94158, USA.; Howard Hughes Medical Institute., Chorba JS; QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA.; University of California San Francisco, Department of Cellular and Molecular Pharmacology, San Francisco, CA, 94158, USA.; Howard Hughes Medical Institute., Lou K; QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA.; University of California San Francisco, Department of Cellular and Molecular Pharmacology, San Francisco, CA, 94158, USA.; Howard Hughes Medical Institute., Dai SA; QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA.; University of California San Francisco, Department of Cellular and Molecular Pharmacology, San Francisco, CA, 94158, USA.; Howard Hughes Medical Institute., Shen W; QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA.; University of California San Francisco, Department of Cellular and Molecular Pharmacology, San Francisco, CA, 94158, USA.; Howard Hughes Medical Institute., Shi Y; QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA.; University of California San Francisco, Department of Cellular and Molecular Pharmacology, San Francisco, CA, 94158, USA.; Howard Hughes Medical Institute., Zhang Z; QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA.; University of California San Francisco, Department of Cellular and Molecular Pharmacology, San Francisco, CA, 94158, USA.; Howard Hughes Medical Institute., Barrio-Hernandez I; European Molecular Biology Laboratory (EMBL), European Bioinformatics Institute, Wellcome Genome Campus, Hinxton, Cambridge, UK., Memon D; European Molecular Biology Laboratory (EMBL), European Bioinformatics Institute, Wellcome Genome Campus, Hinxton, Cambridge, UK., Hernandez-Armenta C; European Molecular Biology Laboratory (EMBL), European Bioinformatics Institute, Wellcome Genome Campus, Hinxton, Cambridge, UK., Mathy CJP; QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA.; Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco.; The UC Berkeley-UCSF Graduate Program in Bioengineering, University of California San Francisco, San Francisco, CA, USA.; University of California San Francisco, Quantitative Biosciences Institute (QBI), San Francisco, CA, 94158, USA., Perica T; QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA.; University of California San Francisco, Quantitative Biosciences Institute (QBI), San Francisco, CA, 94158, USA.; Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco., Pilla KB; QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA.; University of California San Francisco, Quantitative Biosciences Institute (QBI), San Francisco, CA, 94158, USA.; Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco., Ganesan SJ; QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA.; University of California San Francisco, Quantitative Biosciences Institute (QBI), San Francisco, CA, 94158, USA.; Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco., Saltzberg DJ; QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA.; University of California San Francisco, Quantitative Biosciences Institute (QBI), San Francisco, CA, 94158, USA.; Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco., Ramachandran R; QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA.; University of California San Francisco, Quantitative Biosciences Institute (QBI), San Francisco, CA, 94158, USA.; Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco., Liu X; QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA.; University of California San Francisco, Quantitative Biosciences Institute (QBI), San Francisco, CA, 94158, USA.; Department of Pharmaceutical Chemistry, University of California, San Francisco., Rosenthal SB; Center for Computational Biology and Bioinformatics, Department of Medicine, University of California San Diego., Calviello L; Department of Cell and Tissue Biology, University of California, San Francisco., Venkataramanan S; Department of Cell and Tissue Biology, University of California, San Francisco., Liboy-Lugo J; Department of Cell and Tissue Biology, University of California, San Francisco., Lin Y; Department of Cell and Tissue Biology, University of California, San Francisco., Wankowicz SA; QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA.; Biophysics Graduate Program, University of California, San Francisco.; Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco., Bohn M; Department of Pharmaceutical Chemistry, University of California, San Francisco., Sharp PP; University of California San Francisco, Department of Cellular and Molecular Pharmacology, San Francisco, CA, 94158, USA., Trenker R; Cardiovascular Research Institute, University of California San Francisco, San Francisco, CA, 94158, USA., Young JM; Division of Basic Sciences, Fred Hutchinson Cancer Research Center., Cavero DA; J. David Gladstone Institutes, San Francisco, CA 94158, USA., Hiatt J; Medical Scientist Training Program, University of California, San Francisco, CA 94143, USA.; J. David Gladstone Institutes, San Francisco, CA 94158, USA., Roth TL; Medical Scientist Training Program, University of California, San Francisco, CA 94143, USA.; J. David Gladstone Institutes, San Francisco, CA 94158, USA., Rathore U; J. David Gladstone Institutes, San Francisco, CA 94158, USA., Subramanian A; QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA.; George William Hooper Foundation, Department of Microbiology and Immunology, UC San Francisco., Noack J; QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA.; George William Hooper Foundation, Department of Microbiology and Immunology, UC San Francisco., Hubert M; Virus and Immunity Unit, Institut Pasteur, 28 rue du Dr Roux, 75724 Paris Cedex 15, France., Roesch F; Viral Populations and Pathogenesis Unit, CNRS UMR 3569, Institut Pasteur, 28 rue du Dr Roux, 75724 Paris cedex 15, France., Vallet T; Viral Populations and Pathogenesis Unit, CNRS UMR 3569, Institut Pasteur, 28 rue du Dr Roux, 75724 Paris cedex 15, France., Meyer B; Viral Populations and Pathogenesis Unit, CNRS UMR 3569, Institut Pasteur, 28 rue du Dr Roux, 75724 Paris cedex 15, France., White KM; Department for Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY., Miorin L; Department for Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY., Rosenberg OS; Department of Medicine, University of California San Francisco, San Francisco, CA, USA.; Department of Biochemistry and Biophysics, University of California San Francisco, San Francisco, CA, USA.; Chan-Zuckerberg Biohub., Verba KA; QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA.; University of California San Francisco, Quantitative Biosciences Institute (QBI), San Francisco, CA, 94158, USA.; Department of Pharmaceutical Chemistry, University of California, San Francisco., Agard D; QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA.; Biochemistry & Biophysics and Quantitative Biosciences Institute UCSF 600 16th St San Francisco, CA 94143., Ott M; J. David Gladstone Institutes, San Francisco, CA 94158, USA.; Department of Medicine, University of California San Francisco, San Francisco, CA, USA., Emerman M; Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA 98103., Ruggero D; Department of Urology, University of California, San Francisco, San Francisco, CA, USA.; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, 94158, USA.; University of California San Francisco, Department of Cellular and Molecular Pharmacology, San Francisco, CA, 94158, USA., García-Sastre A; Department for Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY., Jura N; QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA.; Cardiovascular Research Institute, University of California San Francisco, San Francisco, CA, 94158, USA.; University of California San Francisco, Department of Cellular and Molecular Pharmacology, San Francisco, CA, 94158, USA., von Zastrow M; QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA.; QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA.; University of California San Francisco, Department of Cellular and Molecular Pharmacology, San Francisco, CA, 94158, USA.; University of California San Francisco, Department of Psychiatry, San Francisco, CA, 94158, USA., Taunton J; QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA.; University of California San Francisco, Quantitative Biosciences Institute (QBI), San Francisco, CA, 94158, USA.; University of California San Francisco, Department of Cellular and Molecular Pharmacology, San Francisco, CA, 94158, USA., Ashworth A; QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA.; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, 94158, USA., Schwartz O; Virus and Immunity Unit, Institut Pasteur, 28 rue du Dr Roux, 75724 Paris Cedex 15, France., Vignuzzi M; Viral Populations and Pathogenesis Unit, CNRS UMR 3569, Institut Pasteur, 28 rue du Dr Roux, 75724 Paris cedex 15, France., d'Enfert C; Direction Scientifique, Institut Pasteur, 28 rue du Dr Roux, 75724 Paris cedex 15, France., Mukherjee S; QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA.; George William Hooper Foundation, Department of Microbiology and Immunology, UC San Francisco., Jacobson M; Department of Pharmaceutical Chemistry, University of California, San Francisco., Malik HS; Division of Basic Sciences, Fred Hutchinson Cancer Research Center., Fujimori DG; QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA.; University of California San Francisco, Department of Cellular and Molecular Pharmacology, San Francisco, CA, 94158, USA.; Department of Pharmaceutical Chemistry, University of California, San Francisco., Ideker T; Division of Genetics, Department of Medicine, University of California San Diego., Craik CS; Department of Pharmaceutical Chemistry, University of California, San Francisco.; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, 94158, USA., Floor S; Department of Cell and Tissue Biology, University of California, San Francisco.; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, 94158, USA., Fraser JS; QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA.; University of California San Francisco, Quantitative Biosciences Institute (QBI), San Francisco, CA, 94158, USA.; Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco., Gross J; QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA.; University of California San Francisco, Quantitative Biosciences Institute (QBI), San Francisco, CA, 94158, USA.; Department of Pharmaceutical Chemistry, University of California, San Francisco., Sali A; QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA.; University of California San Francisco, Quantitative Biosciences Institute (QBI), San Francisco, CA, 94158, USA.; Department of Pharmaceutical Chemistry, University of California, San Francisco.; Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco., Kortemme T; QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA.; Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco.; The UC Berkeley-UCSF Graduate Program in Bioengineering, University of California San Francisco, San Francisco, CA, USA.; University of California San Francisco, Quantitative Biosciences Institute (QBI), San Francisco, CA, 94158, USA., Beltrao P; European Molecular Biology Laboratory (EMBL), European Bioinformatics Institute, Wellcome Genome Campus, Hinxton, Cambridge, UK., Shokat K; QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA.; University of California San Francisco, Department of Cellular and Molecular Pharmacology, San Francisco, CA, 94158, USA.; Howard Hughes Medical Institute., Shoichet BK; QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA.; University of California San Francisco, Quantitative Biosciences Institute (QBI), San Francisco, CA, 94158, USA.; Department of Pharmaceutical Chemistry, University of California, San Francisco., Krogan NJ; QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA.; University of California San Francisco, Quantitative Biosciences Institute (QBI), San Francisco, CA, 94158, USA.; J. David Gladstone Institutes, San Francisco, CA 94158, USA.; University of California San Francisco, Department of Cellular and Molecular Pharmacology, San Francisco, CA, 94158, USA.
Jazyk:	angličtina
Zdroj:	BioRxiv : the preprint server for biology [bioRxiv] 2020 Mar 27. Date of Electronic Publication: 2020 Mar 27.
DOI:	10.1101/2020.03.22.002386
Abstrakt:	An outbreak of the novel coronavirus SARS-CoV-2, the causative agent of COVID-19 respiratory disease, has infected over 290,000 people since the end of 2019, killed over 12,000, and caused worldwide social and economic disruption 1,2 . There are currently no antiviral drugs with proven efficacy nor are there vaccines for its prevention. Unfortunately, the scientific community has little knowledge of the molecular details of SARS-CoV-2 infection. To illuminate this, we cloned, tagged and expressed 26 of the 29 viral proteins in human cells and identified the human proteins physically associated with each using affinity-purification mass spectrometry (AP-MS), which identified 332 high confidence SARS-CoV-2-human protein-protein interactions (PPIs). Among these, we identify 67 druggable human proteins or host factors targeted by 69 existing FDA-approved drugs, drugs in clinical trials and/or preclinical compounds, that we are currently evaluating for efficacy in live SARS-CoV-2 infection assays. The identification of host dependency factors mediating virus infection may provide key insights into effective molecular targets for developing broadly acting antiviral therapeutics against SARS-CoV-2 and other deadly coronavirus strains. Competing Interests: Conflicts: The Krogan Laboratory has received research support from Vir Biotechnology and F. Hoffmann-La Roche. Kevan Shokat has consulting agreements for the following companies involving cash and/or stock compensation: Black Diamond Therapeutics, BridGene Biosciences, Denali Therapeutics, Dice Molecules, eFFECTOR Therapeutics, Erasca, Genentech/Roche, Janssen Pharmaceuticals, Kumquat Biosciences, Kura Oncology, Merck, Mitokinin, Petra Pharma, Qulab Inc. Revolution Medicines, Type6 Therapeutics, Venthera, Wellspring Biosciences (Araxes Pharma). Jack Taunton is a cofounder and shareholder of Global Blood Therapeutics, Principia Biopharma, Kezar Life Sciences, and Cedilla Therapeutics. Jack Taunton and Phillip P. Sharp are listed as inventors on a provisional patent application describing PS3061.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu